Business Wire

Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization

CHICAGO--(BUSINESS WIRE)--Emalex Biosciences today announced that the U.S. Food and Drug Administration has authorized the company’s Expanded Access Program (EAP) for ecopipam, an investigational ...
Monthly Prescribing Reference

Evkeeza Approval Expanded to Include Younger HoFH Patients

The approval of Evkeeza in HoFH patients aged 1 year to less than 5 years was supported by clinical data collected through an expanded access program. The Food and Drug Administration (FDA) has ...
Becker's Hospital Review

Drug approvals to watch in 2026

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

Fast-tracked drug approvals pose safety risks, study shows

A new study co-written by a University of Illinois Urbana-Champaign expert in operations management finds that drugs approved ...
Seeking Alpha

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access ...
Healio

FDA approves Yuflyma for adolescent hidradenitis suppurativa, pediatric uveitis

Please provide your email address to receive an email when new articles are posted on . The FDA approved Yuflyma to treat hidradenitis suppurativa and uveitis in children. The expanded indications ...